Genentek antifibrosis oral therapy was approved by the FDA as a priority for the treatment of patients with specific lung diseases

Interstitional pulmonary disease (ILD) is a class of more than 200 types of rare lung disease.
they have similar characteristics, including coughing and shortness of breath.
, however, each ILD has different causes, treatments, and prognosis.
even after thorough examination, about one in ten patients with ILD remains undiagnosed, and these cases are classified as interstitional lung disease (UILD).
Esbriet (Pirfenidone) is an oral drug approved for the treatment of idiogenic pulmonary fibrosis (IPF), which achieves antifibrosis and inflammation by reducing the level of a range of cytokines and reducing the synthesis of the substitin collagen.
is listed in more than 60 countries around the world.
2020, the FDA awarded Esbriet the qualification and breakthrough therapy for the treatment of ULD.
sNDA is based on the results of a critical, 24-week Phase 2 clinical trial, the first randomized controlled study specifically designed and conducted only in ULD patients.
the data has been published in The Lancet Journal Medicine.
results showed that after 24 weeks, the proportion of patients in the Esbriet group who had a 5% or 10% decrease in force lung capacity (FVC) was significantly lower than in the placebo group.
", Esbriet has become the standard treatment for patients with idiopathic pulmonary fibrosis.
, there are still significant unsealed needs in patients with fibrosis lung disease, including UIDD.
," said Dr. Levi Garraway, Roche's chief medical officer and head of global product development.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
references: .1 FDA Grants Review to Genentech's Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease. Retrieved January 21, 2021, from